Article info

Download PDFPDF

1217 Efficacy and additional mechanism of action of sacituzumab govitecan, a TROP-2 directed antibody-drug conjugate, in preclinical models of non-muscle invasive bladder cancer
Free

Authors

Citation

Chou C, Kornyeyev D, Yang B, et al
1217 Efficacy and additional mechanism of action of sacituzumab govitecan, a TROP-2 directed antibody-drug conjugate, in preclinical models of non-muscle invasive bladder cancer

Publication history

  • First published November 7, 2022.
Online issue publication 
November 07, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.